Jaheli Fuenmayor
About me
Dr. Fuenmayor is an Associate Researcher at the Venezuelan Institute for Scientific Research (IVIC), where she develops antibody-derived molecules of potential immunomodulatory and antitumoral value using both genetic engineering and chemical modifications. She has published her work in academic journals focused on diverse areas such as cancer therapy, nanoparticles, immunology, blood transfusion, and human and veterinary microbiology. Her contributions have been recognized by the Venezuelan Association for Asthma, Allergy and Immunology, the Western New York branch of the American Association of Microbiology and the American Association for Cancer Research.
Since 2016, Dr. Fuenmayor has coordinated the Immunology Graduate Programme at the Center for Advanced Studies (CEA-IVIC), demonstrating a steadfast commitment to advanced scientific education and institutional leadership.
Beyond her laboratory research, Dr. Fuenmayor is actively involved in several community-oriented initiatives in her home country, Venezuela. Her broader impact includes driving social projects focused on food sovereignty, as well as promoting gender equality and intersectionality within scientific environments to foster more equitable academic spaces.
She holds a Master’s Degree in Microbiology and Immunology from the State University of New York at Buffalo, a PhD from IVIC, and has worked as a visiting scholar in several laboratories in France.
Degrees:
15. Albornoz, A., Montaño, R.F.; Fuenmayor, J. (2019). La fusión de un anticuerpo anti-HER2 a C5adesArg aumenta su internalización y disminuye la fosforilación en tirosina inducida por el anticuerpo en células tumorales que sobreexpresan HER2. Revista de Investigación Clínica 60(2): 117-127 (SCI, SciELO).
14. Gamez-Hoyos, R. Pérez, A., Porras, V., Montaño, R.F.; Fuenmayor, J. (2018). Desarrollo, producción y caracterización parcial de un fragmento variable de Ig de cadena sencilla fusionado al Fc de la IgG1 humana (scFv-Fc) con especificidad anti-HER2. Revista de Investigación Clínica 59(3):199-215. doi.org/10.22209/IC.v59n3a01 (SCI, SciELO).
13. Guevara, P., Fuenmayor, J., Thomas, L. (2018). Perspectivas para la formación del postgrado en Biología Aplicada al Diagnóstico de enfermedades causadas por microorganismos. Memorias del Instituto de Biología
Experimental 9:41-44.
12. Albornoz-Loaiza A.; Fandiño, T. Briceño, S.; Fuenmayor, J (2018). Efecto sinérgico de la aplicación conjunta de nanopartículas magnéticas y el anticuerpo trastuzumab sobre células tumorales que sobre-expresan HER2. Revista REDIELUZ 7(1):51-57 (Open Journal Systems).
11. Díaz, D.; Fuenmayor, J; Montano, RF. (2017). Enhanced opsonization of Rhesus-D positive human red blood cells by recombinant polymeric IgG anti-G antibodies. Blood transfusion doi: 10.2450/2017.0176-16 (EMBASE; SCOPUS; PUBMED).
10. Perez-Wiztke, D; Miranda-García, MA ; Suárez, N ; Becerra, R ; Duque, K ; Porras, V ; Fuenmayor, J; Montano, RF. (2016). CTLA4Fcε, a novel soluble fusion protein that binds B7 molecules and the IgE receptors,
and reduces human in vitro soluble CD23 production and lymphocyte proliferation. Immunology. 148(1):40-55. doi: 10.1111/imm.12586. (SCI)
9. Marchi, R; Garmendia, J; Kanzler, D; Fuenmayor, J. (2015) Study of the fibrinolytic process in a patient with antiphospholipid syndrome. Blood Coagulation and Fibrinolysis. 26(3) :239-245. (SCI)
8. Fuenmayor, J; Gamez. R; Montaño, RF. (2013) Anticuerpos monoclonales en el tratamiento del cancer: Terapia dirigida contra tumores sólidos. Revista Venezolana de Oncología. 25(4): 236-254. (EMBASE)
7. Fuenmayor, J; Montaño, RF. (2011) Novel antibody-based proteins for cancer immunotherapy. Cancers 3 (3):3370-3393. (DOAJ, EMBASE)
6. Montaño, RF; Fuenmayor, J. (2011). Enfermedad hemolitica del recien nacido por incompatibilidad materno-fetal del tipo Rh. Mecanismo de accion de la profilaxis con anticuerpos policlonales y su posible reemplazo con anticuerpos monoclonales. Revista Argentina de Transfusión. XXXVII ; No.1 : 31-39.
5. Fuenmayor, J; Perez-Vasquez, K; Perez-Wiztke, D; Montano, RF. (2010). Decreased survival of human breast cancer cells expressing HER2/neu upon in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg . Molecular Cancer Therapeutics 9(8):2175-2185. (SCI)
4. Gueneau, P; Borges, PA; Cedeño, S; Fuenmayor, J; Dominguez-Bello, MG. (2003) Are Nonhuman Primates More Susceptible to Intestinal Helicobacter Infection than Other Animals? Helicobacter 8 (4): 415-416 (SCI, Embase, Academic Search).
3. Gueneau, P; Fuenmayor, J; Aristimuño, OC; Cedeño-Briceño, S.; Báez, E.; Reyes, N.; Michelangeli, F. Domínguez-Bello, M.G. (2002). Are goats naturally resistant to gastric Helicobacter infection?. Veterinary Microbiology. 84 (1-2): 115-121. (SCI)
2. Espinoza, E; Gonzalez, N; Aso, P; Caballero, H; Fuenmayor, J.; Hidalgo, L. (2000). Leucogram in heifers and calves (Holstein) infected with a venezuelan strain of Trypanosoma vivax. Pesquisa Agropecuaria Brasileira. 35 (3): 647-652. (SCI) (SciELO)
1. Fuenmayor, J.; Zang, J.; Ruyechan, W.; Williams, N. (1998). Characterization of two mitochondrial DNA polymerases from Trypanosoma brucei. Journal of Eukaryotic Microbiology. 45 (4): 404-410. (SCI)